KLP Kapitalforvaltning AS Acquires Shares of 43,700 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

KLP Kapitalforvaltning AS bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 4th quarter, Holdings Channel.com reports. The fund bought 43,700 shares of the biopharmaceutical company’s stock, valued at approximately $10,283,000.

A number of other institutional investors have also modified their holdings of ALNY. Natixis Advisors LLC bought a new stake in Alnylam Pharmaceuticals in the third quarter valued at about $2,751,000. Mutual of America Capital Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 26.7% in the 3rd quarter. Mutual of America Capital Management LLC now owns 1,924 shares of the biopharmaceutical company’s stock valued at $529,000 after acquiring an additional 405 shares during the last quarter. Pathstone Holdings LLC increased its holdings in shares of Alnylam Pharmaceuticals by 11.2% in the 3rd quarter. Pathstone Holdings LLC now owns 6,249 shares of the biopharmaceutical company’s stock valued at $1,719,000 after acquiring an additional 629 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 1.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 12,543 shares of the biopharmaceutical company’s stock valued at $3,450,000 after acquiring an additional 144 shares in the last quarter. Finally, Advisors Asset Management Inc. lifted its stake in Alnylam Pharmaceuticals by 4.1% during the third quarter. Advisors Asset Management Inc. now owns 4,767 shares of the biopharmaceutical company’s stock worth $1,311,000 after purchasing an additional 189 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 2.6 %

Shares of ALNY stock opened at $290.70 on Tuesday. The stock has a 50-day simple moving average of $257.81 and a 200 day simple moving average of $260.02. The stock has a market capitalization of $37.63 billion, a P/E ratio of -133.96 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the sale, the executive vice president now owns 12,881 shares in the company, valued at approximately $3,240,344.36. The trade was a 10.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Jeffrey V. Poulton sold 967 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $246,749.39. Following the sale, the chief financial officer now directly owns 32,786 shares of the company’s stock, valued at $8,366,003.62. This represents a 2.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 71,234 shares of company stock valued at $19,958,097. Corporate insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Royal Bank of Canada boosted their target price on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a research note on Friday. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Friday. Morgan Stanley raised their target price on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Canaccord Genuity Group upped their target price on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a report on Friday. Finally, StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty have assigned a buy rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $312.30.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.